Compare FRST & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | RXST |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.2M | 305.0M |
| IPO Year | 2006 | 2021 |
| Metric | FRST | RXST |
|---|---|---|
| Price | $14.58 | $7.25 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.78 |
| AVG Volume (30 Days) | 279.0K | ★ 588.0K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 477.27 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.63 | $10.06 |
| P/E Ratio | $5.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.69 | $5.90 |
| 52 Week High | $14.97 | $16.73 |
| Indicator | FRST | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 51.71 |
| Support Level | $10.55 | $7.27 |
| Resistance Level | $14.97 | $7.72 |
| Average True Range (ATR) | 0.34 | 0.35 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 66.67 | 53.65 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.